In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial
MacroGenics is abruptly shutting down a Phase II trial of its lead experimental drug after seven patients died in the trial.
All 62 patients enrolled …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.